5,8,10,14-Eicosatetraenoic acid, 12-hydroxy-, (E,Z,Z,Z)- | 71030-37-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5,8,10,14-Eicosatetraenoic acid, 12-hydroxy-, (E,Z,Z,Z)-
• 英文别名: (5E,8Z,10Z,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid
• CAS: 71030-37-0
• 化学式: C₂₀H₃₂O₃
• 分子量: 320.5
• InChiKey: ZNHVWPKMFKADKW-FYMOKONMSA-N

物化性质

• 沸点：
  487.7±45.0 °C(Predicted)
• 密度：
  0.984±0.06 g/cm3(Predicted)
• 溶解度：
  0.1 M Na2CO3：2 mg/mL； DMF：可混溶； DMSO：可混溶；乙醇：可混溶； PBS（pH 7.2）：0.8 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2918199090

文献信息

• METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION
  申请人：UNIVERSITY OF MASSACHUSETTS

  公开号：US20200138756A1

  公开（公告）日：2020-05-07

  Disclosed herein are methods and compositions for treating neutrophil-mediated inflammation by targeting, in any combination, the pro-inflammatory MRP2/HXA3 pathway and/or the anti-inflammatory P-gp/endocannabinoid pathway and/or the anti-inflammatory MRP 1/L-AMEND pathway, comprising administering to the subject a therapeutically effective amount of (a) one or more first compound that inhibits the activity and/or level of one or more of multidrug resistance protein 2 (MRP2) and hepoxilin A3 (HXA3) synthase, and/or (b) one or more second compound that increases the level and/or activity of one or more N-acylethanolamines (NAEs), and/or (c) one or more third compound that increases the level and/or activity of multidrug resistance protein 1 (MRP1), wherein the therapeutic amount of the first, second, and third compounds reduces migration of neutrophils into the target tissue.

  本文披露了一种治疗中性粒细胞介导炎症的方法和组合物，通过以任何组合方式靶向抗炎 MRP2/HXA3 途径和/或抗炎 P-gp/内源性大麻素途径和/或抗炎 MRP 1/L-AMEND 途径，包括向受试者施用治疗有效量的（a）抑制一种或多种多药耐药蛋白2（MRP2）和肝过氧化脂酸A3（HXA3）合酶的活性和/或水平的一种或多种第一化合物，和/或（b）增加一种或多种N-乙酰基乙醇胺（NAEs）的水平和/或活性的一种或多种第二化合物，和/或（c）增加一种或多种多药耐药蛋白1（MRP1）的水平和/或活性的一种或多种第三化合物，其中第一、第二和第三化合物的治疗量减少中性粒细胞向目标组织的迁移。
• Biomarkers for sensitive detection of statin-induced muscle toxicity
  申请人：Zora Biosciences OY

  公开号：EP2508895A1

  公开（公告）日：2012-10-10

  The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity.

  本发明特别提供了一种方法及其用途，通过检测生物样本的脂质浓度或脂质-脂质浓度比，并将其与对照组进行比较，预测他汀类药物诱发的肌肉毒性或其并发症，如肌痛、肌病和横纹肌溶解症。与目前使用的临床标记物相比，该方法发现的脂质标记物在检测他汀类药物引起的肌肉毒性方面更具特异性和敏感性。本发明还提供了一种针对上述脂质的抗体，及其用于预测、诊断他汀类药物诱发的肌肉毒性。本发明还涉及包含脂质和/或其抗体的试剂盒，用于预测和/或诊断他汀类药物诱发的肌肉毒性。
• BIOMARKERS FOR SENSITIVE DETECTION OF STATIN-INDUCED MUSCLE TOXICITY
  申请人：Zora Biosciences OY

  公开号：EP2977764A1

  公开（公告）日：2016-01-27

  The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity.

  本发明特别提供了一种方法及其用途，通过检测生物样本的脂质浓度或脂质-脂质浓度比，并将其与对照组进行比较，预测他汀类药物诱发的肌肉毒性或其并发症，如肌痛、肌病和横纹肌溶解症。与目前使用的临床标记物相比，该方法发现的脂质标记物在检测他汀类药物引起的肌肉毒性方面更具特异性和敏感性。本发明还提供了一种针对上述脂质的抗体，及其用于预测、诊断他汀类药物诱发的肌肉毒性。本发明还涉及包含脂质和/或其抗体的试剂盒，用于预测和/或诊断他汀类药物诱发的肌肉毒性。
• US9541565B2
  申请人：——

  公开号：US9541565B2

  公开（公告）日：2017-01-10
• [EN] BIOMARKERS FOR SENSITIVE DETECTION OF STATIN-INDUCED MUSCLE TOXICITY<br/>[FR] MARQUEURS BIOLOGIQUES POUR UNE DÉTECTION SENSIBLE D'UNE TOXICITÉ MUSCULAIRE INDUITE PAR STATINE
  申请人：ZORA BIOSCIENCES OY

  公开号：WO2012136856A1

  公开（公告）日：2012-10-11

  The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity orits complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity.